New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
17:42 EDTCPHD, RHHBYCepheid says Roche patent suit will not have material adverse impact on results
Cepheid (CPHD) management stated that they have not had the opportunity to review the claim made by Roche (RHHBY) regarding a patent suit filed earlier; however management stated that it is their understanding that the patent has expired. Either way, the lawsuit will not have a material adverse impact on the company's results.
News For CPHD;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
October 21, 2014
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
October 16, 2014
17:35 EDTCPHDCepheid 'well positioned' to address Ebola
Subscribe for More Information
17:28 EDTCPHDCepheid sees Q4 adjusted EPS 2c-4c, may not compare to consensus (9c)
Subscribe for More Information
16:11 EDTCPHDCepheid sees FY14 adjusted EPS 11c-13c, may not compare to consensus (52c)
Subscribe for More Information
16:09 EDTCPHDCepheid reports Q3 EPS ex-items 6c, consensus (16c)
Subscribe for More Information
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:48 EDTCPHDCepheid recent weakness unjustified, says Canaccord
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use